Policymaking through Adjudication: DEA’s Red Flags
DEA's red flags policy has made some pharmacies reluctant to fill prescriptions for buprenorphine, a drug that can help tackle the opioid crisis.
Commentaries & Insights
Our Commentaries and Insights are short-form publications intended to distill long-form research and synthesize current policymaking activity into easily understood concepts.
Court Decision Extends the Period for Issuing Midnight Rules
A court decision found that agencies cannot withdraw a final rule that has appeared in the Federal Register for public inspection without notice and comment.
Factors Contributing to the Infant Formula Shortage
To reduce the risk of infant formula shortages in the future, the government should eliminate the barriers to entry under its control.
Nostalgia for Agency Expertise
Calls for more deference to agency expertise derive from an unrealistic view of executive policymaking.
Is Chevron Deference Still Alive?
Three takeaways follow from the Supreme Court’s recent opinions ignoring Chevron v. NRDC.
Biden's Spring 2022 Unified Agenda
The Spring 2022 Unified Agenda suggests the Biden administration is focusing on priorities related to the environment, health, immigration, and education.
From Fragility to Agility: The Future of Regulation
The National Academy of Public Administration offers an agile regulatory framework to enhance government responsiveness to current and future challenges. The report includes tenets and practices that can improve public management and regulatory outcomes.
The Unintended Consequences of Banking Regulations: Shadow Banking
Shadow banks are not subject to the stringent regulation that traditional banks are and can pose great risks to the financial system. Since the financial crisis, banking regulations have been tightened to reduce the fragility of the financial system.
FDA Struggles to Pinpoint Impacts of Proposed Rule
In February, the Food and Drug Administration (FDA) released a long-awaited proposed rule creating national standards for companies in the prescription drug supply chain.
In recent years, the Chinese government has increasingly flexed its economic, political, and military muscles around the world. Close to its mainland home has been no exception, as the Chinese government has taken actions to pressure officials in Hong Kong and Taiwan.